Literature DB >> 12833918

Nevirapine: an option for preventing as well as treating paediatric HIV infection.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12833918      PMCID： PMC2704453     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN： 1680-6905            Impact factor:   0.927


× No keyword cloud information.
  13 in total

1.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  N Shaffer; R Chuachoowong; P A Mock; C Bhadrakom; W Siriwasin; N L Young; T Chotpitayasunondh; S Chearskul; A Roongpisuthipong; P Chinayon; J Karon; T D Mastro; R J Simonds
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Nov-Dec

Review 3.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

4.  Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.

Authors:  K Luzuriaga; Y Bryson; P Krogstad; J Robinson; B Stechenberg; M Lamson; S Cort; J L Sullivan
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

5.  6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant.

Authors:  F Dabis; P Msellati; N Meda; C Welffens-Ekra; B You; O Manigart; V Leroy; A Simonon; M Cartoux; P Combe; A Ouangré; R Ramon; O Ky-Zerbo; C Montcho; R Salamon; C Rouzioux; P Van de Perre; L Mandelbrot
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

6.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Authors:  J B Jackson; G Becker-Pergola; L A Guay; P Musoke; M Mracna; M G Fowler; L M Mofenson; M Mirochnick; F Mmiro; S H Eshleman
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

Review 7.  Nevirapine: pharmacokinetic considerations in children and pregnant women.

Authors:  M Mirochnick; D F Clarke; A Dorenbaum
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

8.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

9.  Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.

Authors:  E Marseille; J G Kahn; F Mmiro; L Guay; P Musoke; M G Fowler; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

10.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.